Antibody Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Antibody Manufactured, Type of Expression System Used, Scale of Operation and Geographical Regions

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

5.1. Chapter Overview
5.2. Concept of an Antibody
5.3. Structure of an Antibody
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Types of Antibodies
5.6.1. Monoclonal Antibodies
5.6.2. Bispecific Antibodies
5.6.3. Polyclonal Antibodies
5.7. Overview of Contract Manufacturing
5.8. Need for Outsourcing in the Biopharmaceutical Industry
5.9. Advantages of Outsourcing Manufacturing Services

6.1. Chapter Overview
6.2. Antibody Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Location of Antibody Manufacturing Facilities
6.2.5. Analysis by Scale of Operation
6.2.6. Analysis by Type of Antibody Manufactured
6.2.7. Analysis by Expression System Used
6.2.8. Analysis by Fill / Finish Services Offered

7.1. Chapter Overview
7.2. Assumptions and Key Input Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
7.5. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
7.6. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia-Pacific

8.1. Chapter Overview
8.2. AGC Biologics
8.2.1. Company Overview
8.2.2. Antibody Contract Manufacturing Service Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. Aldeveron
8.3.1. Company Overview
8.3.2. Antibody Contract Manufacturing Service Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. Emergent Biosolutions
8.4.1. Company Overview
8.4.2. Antibody Contract Manufacturing Service Portfolio
8.4.3. Recent Developments and Future Outlook
8.5. Eurofins CDMO
8.5.1. Company Overview
8.5.2. Antibody Contract Manufacturing Service Portfolio
8.5.3. Future Outlook
8.6. FUJIFILM Diosynth Biotechnologies
8.6.1. Company Overview
8.6.2. Antibody Contract Manufacturing Service Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. KBI Biopharma
8.7.1. Company Overview
8.7.2. Antibody Contract Manufacturing Service Portfolio
8.7.3. Recent Developments and Future Outlook
8.8. Lonza
8.8.1. Company Overview
8.8.2. Antibody Contract Manufacturing Service Portfolio
8.8.3. Recent Developments and Future Outlook
8.9. Nitto Avecia Pharma Services
8.9.1. Company Overview
8.9.2. Antibody Contract Manufacturing Service Portfolio
8.9.3. Recent Developments and Future Outlook
8.10. Novasep
8.10.1. Company Overview
8.10.2. Antibody Contract Manufacturing Service Portfolio
8.10.3. Future Outlook
8.11. Pierre Fabre
8.11.1. Company Overview
8.11.2. Antibody Contract Manufacturing Service Portfolio
8.11.3. Recent Developments and Future Outlook
8.12. Samsung Biologics
8.12.1. Company Overview
8.12.2. Antibody Contract Manufacturing Service Portfolio
8.12.3. Recent Developments and Future Outlook
8.13. Synthon
8.13.1. Company Overview
8.13.2. Antibody Contract Manufacturing Service Portfolio
8.13.3. Recent Developments and Future Outlook
8.14. Thermo Fisher Scientific
8.14.1. Company Overview
8.14.2. Antibody Contract Manufacturing Service Portfolio
8.14.3. Recent Developments and Future Outlook

9.1. Chapter Overview
9.2. ABL
9.2.1. Company Overview
9.2.2. Antibody Contract Manufacturing Service Portfolio
9.3. Abzena
9.3.1. Company Overview
9.3.2. Antibody Contract Manufacturing Service Portfolio
9.4. Allele Biotechnology & Pharmaceuticals
9.4.1. Company Overview
9.4.2. Antibody Contract Manufacturing Service Portfolio
9.5. Alvotech
9.5.1. Company Overview
9.5.2. Antibody Contract Manufacturing Service Portfolio
9.6. Antibody Production Services
9.6.1. Company Overview
9.6.2. Antibody Contract Manufacturing Service Portfolio
9.7. Arabio
9.7.1. Company Overview
9.7.2. Antibody Contract Manufacturing Service Portfolio
9.8. Bharat Serums and Vaccines
9.8.1. Company Overview
9.8.2. Antibody Contract Manufacturing Service Portfolio
9.9. Boehringer Ingelheim
9.9.1. Company Overview
9.9.2. Antibody Contract Manufacturing Service Portfolio
9.10. Glenmark Pharmaceuticals
9.10.1. Company Overview
9.10.2. Antibody Contract Manufacturing Service Portfolio
9.11. MilliporeSigma
9.11.1. Company Overview
9.11.2. Antibody Contract Manufacturing Service Portfolio
9.12. Siam Bioscience
9.12.1. Company Overview
9.12.2. Antibody Contract Manufacturing Service Portfolio

10.1. Chapter Overview
10.2. Small Molecules and Biologics
10.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
10.2.2. Comparison of Key Characteristics
10.2.3. Comparison of Manufacturing Processes
10.2.4. Comparison of Key Manufacturing related Challenges

11.1. Chapter Overview
11.2. Methodology
11.3. Antibody Contract Manufacturers: Benchmarking Analysis
11.3.1. Benchmark Analysis of Small Players Based in North America (Peer Group I)
11.3.2. Benchmark Analysis of Mid-Sized Players Based in North America (Peer Group II)
11.3.3. Benchmark Analysis of Large Players Based in North America (Peer Group III)
11.3.4. Benchmark Analysis of Very Large Players Based in North America (Peer Group IV)
11.3.5. Benchmark Analysis of Small Players Based in Europe (Peer Group V)
11.3.6. Benchmark Analysis of Mid-Sized Players Based in Europe (Peer Group VI)
11.3.7. Benchmark Analysis of Large Players Based in Europe (Peer Group VII)
11.3.8. Benchmark Analysis of Very Large Players Based in Europe (Peer Group VIII)
11.3.9. Benchmark Analysis of Small Players Based in Asia-Pacific (Peer Group IX)
11.3.10. Benchmark Analysis of Mid-Sized Players Based in Asia-Pacific (Peer Group X)
11.3.11. Benchmark Analysis of Large Players Based in Asia-Pacific (Peer Group XI)
11.3.12. Benchmark Analysis of Very Large Players Based in Asia-Pacific (Peer Group XII)
11.4. Concluding Remarks

12.1. Chapter Overview
12.2. Partnerships Models
12.3. Antibody Contract Manufacturing: List of Partnerships
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Type of Antibody Manufactured
12.3.5. Analysis by Project Scale
12.3.6. Analysis by Focus Therapeutic Area
12.3.7. Most Active Players: Analysis by Number of Partnerships and Type of Partnership
12.3.8. Geographical Analysis
12.3.8.1. Continent-wise Distribution
12.3.8.2. Country-wise Distribution

13.1. Chapter Overview
13.2. Antibody Contract Manufacturers: List of Expansions
13.2.1. Analysis by Year of Expansion
13.2.2. Analysis by Type of Expansion
13.2.3. Analysis by Type of Antibody Manufactured
13.2.4. Analysis by Location of Manufacturing Facility
13.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion
13.2.6. Analysis of Most Active Players by Number of Expansions
13.2.7. Geographical Analysis
13.2.7.1. Country-wise Distribution

14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Antibody Contract Manufacturing: Installed Global Capacity
14.3.1. Analysis by Scale of Operation
14.3.3. Analysis by Type of Expression System Used
14.3.4. Analysis by Location of Manufacturing Facility
14.4. Concluding Remarks

15.1 Chapter Overview
15.2 Assumptions and Methodology
15.3 Antibody Contract Manufacturing Market: Overall Annual Demand
15.3.1. Analysis by Scale of Operation
15.3.2. Analysis by Geography

16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Antibody Contract Manufacturing Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
17.3.1 Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario
17.4. Key Market Segmentations

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Antibody Contract Manufacturing Market: Distribution by Type of Antibody Manufactured, 2019, 2024 and 2035
18.3.1. Antibody Contract Manufacturing Market for Monoclonal Antibodies: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
18.3.2. Antibody Contract Manufacturing Market for Bispecific Antibodies: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
18.4. Data Triangulation and Validation

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Antibody Contract Manufacturing Market: Distribution by Scale of Operation, 2019, 2024 and 2035
19.3.1. Antibody Contract Manufacturing Market at Commercial Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
19.3.2. Antibody Contract Manufacturing Market at Clinical Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
19.4. Data Triangulation and Validation

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Antibody Contract Manufacturing Market: Distribution by Type of Expression System Used, 2019, 2024 and 2035
20.3.1. Antibody Contract Manufacturing Market for Mammalian Expression System: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2. Antibody Contract Manufacturing Market for Microbial Expression System: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
20.4. Data Triangulation and Validation

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Antibody Contract Manufacturing Market: Distribution by Key Geographical Regions, 2019, 2024 and 2035
21.3.1. Antibody Contract Manufacturing Market in North America: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
21.3.2. Antibody Contract Manufacturing Market in Europe: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.3.1. Antibody Contract Manufacturing Market in Asia: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
21.3.2. Antibody Contract Manufacturing Market in Latin America: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.3.1. Antibody Contract Manufacturing Market in Middle East and North Africa: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
21.4. Data Triangulation and Validation

22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Concluding Remarks

23.1. Chapter Overview
23.2. Rise in Outsourcing Activity
23.3. Shift from One-time Contractual Engagements to Strategic Partnerships
23.4. Adoption of New and Innovative Technologies
23.5. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
23.6. Capability and Expertise Expansions by CMOs to become One Stop Shops
23.7. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
23.8. Challenges Faced by both Sponsors and Service Providers
23.9. Factors Influencing the Future of Antibody Contract Manufacturing Market
23.10. Concluding Remarks

24.1. Chapter Overview
24.2. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
24.3. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
24.4. Patrica, Business Development and Marketing Manager, 53 Biologics
24.5. Daniel, Business Development Manager, EirGenix
24.6. Michiel Stork, Business Development Manager, ProBiogen
24.7. Judyta Suskiewicz, Business Development Specialist, Mabion

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Economic and Other Project Specific Consideration: Lesson Learnt from Past Recessions
Figure 4.1 Executive Summary: Antibody Contract Manufacturing Market Landscape
Figure 4.2 Executive Summary: Partnerships
Figure 4.3 Executive Summary: Recent Expansions
Figure 4.4 Executive Summary: Capacity Analysis
Figure 4.5 Executive Summary: Demand Analysis
Figure 4.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Historical Timelines of Antibodies
Figure 5.2 Structure of an Antibody
Figure 5.3 Mechanism of Action of Antibodies
Figure 5.4 Monoclonal Antibody Production
Figure 5.5 Symmetric and Asymmetric Bispecific Antibodies
Figure 5.6 Mechanism of Action of Bispecific Antibodies
Figure 5.7 Polyclonal Antibody Production
Figure 5.8 Applications of Polyclonal Antibodies
Figure 5.9 Types of Third-Party Service Providers
Figure 6.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 Antibody Contract Manufacturers: Distribution by Company Size
Figure 6.3 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region)
Figure 6.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country)
Figure 6.5 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 6.6 Antibody Contract Manufacturers: Distribution by Location Scale of Operation
Figure 6.7 Antibody Contract Manufacturers: Distribution by Type of Antibody Manufactured
Figure 6.8 Antibody Contract Manufacturers: Distribution by Type of Expression System Used
Figure 6.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
Figure 7.1 Company Competitiveness Analysis: Very Large Antibody Contract Manufacturers based in North America
Figure 7.2 Company Competitiveness Analysis: Large Antibody Contract Manufacturers based in North America
Figure 7.3 Company Competitiveness Analysis: Mid-Sized Antibody Contract Manufacturers based in North America
Figure 7.4 Company Competitiveness Analysis: Small Antibody Contract Manufacturers based in North America
Figure 7.5 Company Competitiveness Analysis: Very Large Antibody Contract Manufacturers based in Europe
Figure 7.6 Company Competitiveness Analysis: Large Antibody Contract Manufacturers based in Europe
Figure 7.7 Company Competitiveness Analysis: Mid-Sized Antibody Contract Manufacturers based in Europe
Figure 7.8 Company Competitiveness Analysis: Small Antibody Contract Manufacturers based in Europe
Figure 7.9 Company Competitiveness Analysis: Very Large Antibody Contract Manufacturers based in Asia
Figure 7.10 Company Competitiveness Analysis: Large Antibody Contract Manufacturers based in Asia
Figure 7.11 Company Competitiveness Analysis: Mid-Sized Antibody Contract Manufacturers based in Asia
Figure 7.12 Company Competitiveness Analysis: Small Antibody Contract Manufacturers based in Asia
Figure 10.1 Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2023
Figure 10.2 Comparison of Key Characteristics of Small Molecules and Biologics
Figure 10.3 Comparison of Manufacturing Processes of Small Molecules and Biologics
Figure 11.1 Benchmark Analysis: Distribution by Region and Company Size
Figure 11.2 Benchmark Analysis: Small Players Based in North America (Peer Group I)
Figure 11.3 Benchmark Analysis: Mid-Sized Players Based in North America (Peer Group II)
Figure 11.4 Benchmark Analysis: Large Players Based in North America (Peer Group III)
Figure 11.5 Benchmark Analysis: Very Large Players Based in North America (Peer Group IV)
Figure 11.6 Benchmark Analysis: Small Players Based in Europe (Peer Group V)
Figure 11.7 Benchmark Analysis: Mid-Sized Players Based in Europe (Peer Group VI)
Figure 11.8 Benchmark Analysis: Large Players Based in Europe (Peer Group VII)
Figure 11.9 Benchmark Analysis: Very Large Players Based in Europe (Peer Group VIII)
Figure 11.10 Benchmark Analysis: Small Players Based in Asia (Peer Group IX)
Figure 11.11 Benchmark Analysis: Mid-Sized Players Based in Asia (Peer Group X)
Figure 11.12 Benchmark Analysis: Large Players Based in Asia (Peer Group XI)
Figure 11.13 Benchmark Analysis: Very Large Players Based in Asia (Peer Group XII)
Figure 11.14 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
Figure 12.1 Partnerships: Distribution by Year of Partnership
Figure 12.2 Partnerships: Distribution by Type of Partnership
Figure 12.3 Partnerships: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships: Distribution by Type of Antibody Manufactured
Figure 12.5 Partnerships: Distribution by Project Scale
Figure 12.6 Partnerships: Distribution by Target Therapeutic Area
Figure 12.7 Partnerships: Most Active Players
Figure 12.8 Partnerships: Country-wise Distribution
Figure 12.9 Partnerships: Continent-wise Distribution
Figure 13.1 Recent Expansions: Distribution by Year of Expansion
Figure 13.2 Recent Expansions: Distribution by Type of Expansion
Figure 13.3 Recent Expansions: Distribution by Type of Antibody
Figure 13.4 Recent Expansions: Distribution by Type of Antibody and Type of Expansion
Figure 13.5 Recent Expansions: Distribution by Location of Facility (Region-wise)
Figure 13.6 Recent Expansions: Distribution by Location of Facility (Country-wise)
Figure 13.7 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
Figure 13.8 Recent Expansions: Most Active Players
Figure 13.9 Recent Expansions: Distribution by Local and International Expansions
Figure 14.1 Capacity Analysis: Distribution by Company Size
Figure 14.2 Capacity Analysis: Distribution by Scale of Operation
Figure 14.3 Capacity Analysis: Distribution by Type of Expression System Used
Figure 14.4 Capacity Analysis: Distribution by Location of Manufacturing Facility
Figure 14.5 Capacity Analysis: Distribution by Location of Manufacturing Facility and Scale of Operation
Figure 14.6 Capacity Analysis: Distribution by Location of Manufacturing Facility and Company Size
Figure 15.1 Global Demand for Antibodies, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (in Kilograms)
Figure 15.2 Global Demand for Antibodies: Distribution by Scale of Operation (in Kilograms)
Figure 15.3 Global Demand for Antibodies: Distribution by Geographical Region, 2023-2035 (in Kilogram)
Figure 16.1 Antibody Contract Manufacturing: Market Drivers
Figure 16.2 Antibody Contract Manufacturing: Market Restraints
Figure 16.3 Antibody Contract Manufacturing: Market Opportunities
Figure 16.4 Antibody Contract Manufacturing: Market Challenges
Figure 17.1 Global Antibody Contract Manufacturing Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.2 Global Antibody Contract Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Figure 17.3 Global Antibody Contract Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Figure 18.1 Antibody Contract Manufacturing Market: Distribution by Type of Antibody Manufactured, 2019, 2024 and 2035
Figure 18.2 Antibody Contract Manufacturing Market for Monoclonal Antibodies: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.3 Antibody Contract Manufacturing Market for Bispecific Antibodies: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.1 Antibody Contract Manufacturing Market: Distribution by Scale of Operation, 2019, 2023 and 2035
Figure 19.2 Antibody Contract Manufacturing Market at Commercial Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.3 Antibody Contract Manufacturing Market at Clinical Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.1 Antibody Contract Manufacturing Market: Distribution by Type of Expression System Used, 2019, 2023 and 2035
Figure 20.2 Antibody Contract Manufacturing Market for Mammalian Expression System: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.3 Antibody Contract Manufacturing Market for Microbial Expression System: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.1 Antibody Contract Manufacturing Market: Distribution by Geographical Region, 2019, 2023 and 2035
Figure 21.2 Antibody Contract Manufacturing Market in North America: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.3 Antibody Contract Manufacturing Market in Europe: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.4 Antibody Contract Manufacturing Market in Asia: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.5 Antibody Contract Manufacturing Market in Latin America: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.6 Antibody Contract Manufacturing Market in Middle East and North Africa: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 23.1 Antibody Contract Manufacturing: SWOT Analysis
Figure 23.2 Comparison of SWOT Factors: Harvey Ball Analysis

Table 5.1 Key Features of Antibody Isotypes
Table 5.2 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
Table 5.3 List of Approved Monoclonal Antibodies
Table 5.4 Difference between Polyclonal and Monoclonal Antibodies
Table 6.1 List of Antibody Contract Manufacturers
Table 6.2 Antibody Contract Manufacturers: Information on Scale of Operation
Table 6.3 Antibody Contract Manufacturers: Information on Type of Antibody Manufactured
Table 6.4 Antibody Contract Manufacturers: Information on Type of Expression System Used
Table 6.5 Antibody Contract Manufacturers: Information on Fill / Finish Services Offered
Table 8.1 AGC Biologics: Company Overview
Table 8.2 AGC Biologics: Antibody Contract Manufacturing Service Portfolio
Table 8.3 AGC Biologics: Recent Development and Future Outlook
Table 8.4 Aldeveron: Company Overview
Table 8.5 Aldeveron: Antibody Contract Manufacturing Service Portfolio
Table 8.6 Aldeveron: Recent Development and Future Outlook
Table 8.7 Emergent BioSolutions: Company Overview
Table 8.8 Emergent BioSolutions: Antibody Contract Manufacturing Service Portfolio
Table 8.9 Emergent BioSolutions: Recent Development and Future Outlook
Table 8.10 Eurofins CDMO: Company Overview
Table 8.11 Eurofins CDMO: Antibody Contract Manufacturing Service Portfolio
Table 8.12 Eurofins CDMO: Recent Development and Future Outlook
Table 8.13 Fujifilm Diosynth Biotechnologies: Company Overview
Table 8.14 Fujifilm Diosynth Biotechnologies: Antibody Contract Manufacturing Service Portfolio
Table 8.15 Fujifilm Diosynth Biotechnologies: Recent Development and Future Outlook
Table 8.16 KBI Biopharma: Company Overview
Table 8.17 KBI Biopharma: Antibody Contract Manufacturing Service Portfolio
Table 8.18 KBI Biopharma: Recent Development and Future Outlook
Table 8.19 Lonza: Company Overview
Table 8.20 Lonza: Antibody Contract Manufacturing Service Portfolio
Table 8.21 Lonza: Recent Development and Future Outlook
Table 8.22 Nitto Avecia Pharma: Company Overview
Table 8.23 Nitto Avecia Pharma: Antibody Contract Manufacturing Service Portfolio
Table 8.24 Nitto Avecia Pharma: Recent Development and Future Outlook
Table 8.25 Novasep: Company Overview
Table 8.26 Novasep: Antibody Contract Manufacturing Service Portfolio
Table 8.27 Novasep: Recent Development and Future Outlook
Table 8.28 Pierre Fabre: Company Overview
Table 8.29 Pierre Fabre: Antibody Contract Manufacturing Service Portfolio
Table 8.30 Pierre Fabre: Recent Development and Future Outlook
Table 8.31 Samsung Biologics: Company Overview
Table 8.32 Samsung Biologics: Antibody Contract Manufacturing Service Portfolio
Table 8.33 Samsung Biologics: Recent Development and Future Outlook
Table 8.34 Synthon: Company Overview
Table 8.35 Synthon: Antibody Contract Manufacturing Service Portfolio
Table 8.36 Synthon: Recent Development and Future Outlook
Table 8.37 Thermo Fisher Scientific: Company Overview
Table 8.38 Thermo Fisher Scientific: Antibody Contract Manufacturing Service Portfolio
Table 8.39 Thermo Fisher Scientific: Recent Development and Future Outlook
Table 9.1 ABL: Company Overview
Table 9.2 ABL: Antibody Contract Manufacturing Service Portfolio
Table 9.1 Absolute Antibody: Company Overview
Table 9.2 Absolute Antibody: Antibody Contract Manufacturing Service Portfolio
Table 9.1 Abzena: Company Overview
Table 9.2 Abzena: Antibody Contract Manufacturing Service Portfolio
Table 9.1 Allele Biotechnology & Pharmaceuticals: Company Overview
Table 9.2 Allele Biotechnology & Pharmaceuticals: Antibody Contract Manufacturing Service Portfolio
Table 9.1 Alvotech: Company Overview
Table 9.2 Alvotech: Antibody Contract Manufacturing Service Portfolio
Table 9.1 Antibody Production Services: Company Overview
Table 9.2 Antibody Production Services (Division of Life Science Group): Antibody Contract Manufacturing Service Portfolio
Table 9.1 Arabio: Company Overview
Table 9.2 Arabio: Antibody Contract Manufacturing Service Portfolio
Table 9.1 Bharat Serums and Vaccines: Company Overview
Table 9.2 Bharat Serums and Vaccines: Antibody Contract Manufacturing Service Portfolio
Table 9.1 Boehringer Ingelheim: Company Overview
Table 9.2 Boehringer Ingelheim: Antibody Contract Manufacturing Service Portfolio
Table 9.1 Glenmark Pharmaceuticals: Company Overview
Table 9.2 Glenmark Pharmaceuticals: Antibody Contract Manufacturing Service Portfolio
Table 9.1 MilliporeSigma: Company Overview
Table 9.2 MilliporeSigma: Antibody Contract Manufacturing Service Portfolio
Table 9.1 Siam Bioscience: Company Overview
Table 9.2 Siam Bioscience: Antibody Contract Manufacturing Service Portfolio
Table 10.1 Comparison of Strengths and Weaknesses of Small Molecules and Biologics
Table 10.2 Comparison of Development Characteristics of Small Molecules and Biologics
Table 11.1 Benchmark Analysis: Information on Peer Groups
Table 12.1 Antibody Contract Manufacturing: List of Partnerships, 2013-2019
Table 12.2 Antibody Contract Manufacturer Partnerships: Information on Type of Antibodies, Project Scale and Therapeutic Area
Table 13.1 Antibody Contract Manufacturing: List of Expansions, 2017-2019
Table 13.2 Antibody Contract Manufacturing Expansions: Information on Type of Antibodies
Table 14.1 Capacity Analysis: Average Capacity for Mammalian Expression System
Table 14.2 Capacity Analysis: Average Capacity for Microbial Expression System
Table 14.3 Capacity Analysis: Installed Global Capacity
Table 14.1 Patent Approval Information of Best-selling Biologics
Table 26.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
Table 26.2 Antibody Contract Manufacturers: Distribution by Company Size
Table 26.3 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 26.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 26.5 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 26.6 Antibody Contract Manufacturers: Distribution by Scale of Operation
Table 26.7 Antibody Contract Manufacturers: Distribution by Type of Antibody Manufactured
Table 26.8 Antibody Contract Manufacturers: Distribution by Expression System Used
Table 26.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
Table 26.12 Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2019
Table 26.10 Partnerships: Distribution by Year of Partnership
Table 26.11 Partnerships: Distribution by Type of Partnership
Table 26.12 Partnerships: Distribution by Year and Type of Partnership
Table 26.13 Partnerships: Distribution by Type of Antibody
Table 26.14 Partnerships: Distribution by Project Scale
Table 26.15 Partnerships: Distribution by Focus Therapeutic Area
Table 26.16 Partnerships: Most Active Players
Table 26.17 Partnerships: Country-wise Distribution
Table 26.18 Recent Expansions: Distribution by Year of Expansion
Table 26.19 Recent Expansions: Distribution by Type of Expansion
Table 26.20 Recent Expansions: Distribution by Type of Antibody
Table 26.21 Recent Expansions: Distribution by Type of Antibody and Type of Expansion
Table 26.22 Recent Expansions: Distribution by Location of Facility (Region-wise)
Table 26.23 Recent Expansions: Distribution by Location of Facility (Country-wise)
Table 26.24 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
Table 26.25 Recent Expansions: Most Active Players
Table 26.26 Recent Expansions: Distribution by Local and International Expansions
Table 26.27 Capacity Analysis: Distribution by Company Size
Table 26.28 Capacity Analysis: Distribution by Scale of Operation
Table 26.29 Capacity Analysis: Distribution by Type of Expression System Used
Table 26.30 Capacity Analysis: Distribution by Location of Manufacturing Facility
Table 26.31 Demand Analysis: Annual Demand for Antibodies (in Kilograms)
Table 26.32 Demand Analysis: Distribution by Scale of Operation (in Kilograms)
Table 26.33 Demand Analysis: Distribution by Geographical Location
Table 26.34 Global Antibody Contract Manufacturing Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.35 Global Antibody Contract Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Table 26.36 Global Antibody Contract Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Table 26.37 Antibody Contract Manufacturing Market: Distribution by Type of Antibody Manufactured, 2019, 2024 and 2035
Table 26.38 Antibody Contract Manufacturing Market for Monoclonal Antibodies: Historical Trends (2019-2023) (USD Billion)
Table 26.39 Antibody Contract Manufacturing Market for Monoclonal Antibodies: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.40 Antibody Contract Manufacturing Market for Bispecific Antibodies: Historical Trends (2019-2023) (USD Billion)
Table 26.41 Antibody Contract Manufacturing Market for Bispecific Antibodies: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.42 Antibody Contract Manufacturing Market: Distribution by Scale of Operation, 2019, 2024 and 2035
Table 26.43 Antibody Contract Manufacturing Market at Commercial Scale: Historical Trends (2019-2023) (USD Billion)
Table 26.44 Antibody Contract Manufacturing Market at Commercial Scale: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.45 Antibody Contract Manufacturing Market at Clinical Scale: Historical Trends (2019-2023) (USD Billion)
Table 26.46 Antibody Contract Manufacturing Market at Clinical Scale: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.47 Antibody Contract Manufacturing Market: Distribution by Type of Expression System Used, 2019, 2024 and 2035
Table 26.48 Antibody Contract Manufacturing Market for Mammalian Expression System: Historical Trends (2019-2023) (USD Billion)
Table 26.49 Antibody Contract Manufacturing Market for Mammalian Expression System: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.50 Antibody Contract Manufacturing Market for Microbial Expression System: Historical Trends (2019-2023) (USD Billion)
Table 26.51 Antibody Contract Manufacturing Market for Microbial Expression System: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.52 Antibody Contract Manufacturing Market: Distribution by Geographical Region, 2019, 2024 and 2035
Table 26.53 Antibody Contract Manufacturing Market in North America: Historical Trends (2019-2023) (USD Billion)
Table 26.54 Antibody Contract Manufacturing Market in North America: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.55 Antibody Contract Manufacturing Market in Europe: Historical Trends (2019-2023) (USD Billion)
Table 26.56 Antibody Contract Manufacturing Market in Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.57 Antibody Contract Manufacturing Market in Asia: Historical Trends (2019-2023) (USD Billion)
Table 26.58 Antibody Contract Manufacturing Market in Asia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.59 Antibody Contract Manufacturing Market in Latin America: Historical Trends (2019-2023) (USD Billion)
Table 26.60 Antibody Contract Manufacturing Market in Latin America: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.61 Antibody Contract Manufacturing Market in Middle East and North Africa: Historical Trends (2019-2023) (USD Billion)
Table 26.62 Antibody Contract Manufacturing Market in Middle East and North Africa: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)